Tourmaline Bio (NASDAQ:TRML – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04, Zacks reports.
Tourmaline Bio Trading Down 3.9 %
Tourmaline Bio stock opened at $13.97 on Friday. The firm has a market capitalization of $358.29 million, a price-to-earnings ratio of -2.15 and a beta of 2.31. The firm’s fifty day moving average price is $14.80 and its two-hundred day moving average price is $22.72. Tourmaline Bio has a 1-year low of $9.18 and a 1-year high of $48.31.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $48.00 target price on shares of Tourmaline Bio in a research note on Tuesday, May 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $61.80.
About Tourmaline Bio
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
See Also
- Five stocks we like better than Tourmaline Bio
- How to Evaluate a Stock Before Buying
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Market Cap Calculator: How to Calculate Market Cap
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.